CVA blood pressure guidline
Reading File
Searching PubMed
stroke blood pressure management guidelines
Finding Sources
Finding Sources
Reading Article
PMID: 40401775
Reading File
Reading File
Reading File
Reading File
Searching the Web
AHA ASA 2024 2025 ischemic stroke blood pressure guidelines acute management
Reading Web Page
https://www.ahajournals.org/doi/10.1161/STR.0000000000000513
Searching the Web
2026 AHA ASA guideline acute ischemic stroke blood pressure targets recommendations
Excellent - I now have comprehensive data from multiple authoritative sources including the brand new 2026 AHA/ASA guideline. Here is the full structured answer:
CVA Blood Pressure Guidelines
Blood pressure (BP) management in stroke differs significantly depending on stroke type (ischemic vs. hemorrhagic) and phase (acute vs. subacute vs. secondary prevention). The 2026 AHA/ASA Guideline for the Early Management of Acute Ischemic Stroke is the most current reference.
1. Acute Ischemic Stroke (AIS)
A. Patients NOT receiving reperfusion therapy (no tPA, no EVT)
- Permissive hypertension is the standard approach. The penumbra (ischemic but viable brain tissue surrounding the core infarct) depends on collateral perfusion that is pressure-driven.
- Treat only if BP >220/120 mmHg - no benefit has been shown for treating below this threshold in non-reperfusion patients.
- If BP does require treatment, lower gradually by ~15% in the first 24 hours.
- There is no specific target for patients not eligible for reperfusion therapy.
"Permissive hypertension allows for maximal cerebral perfusion. Systolic blood pressure >180 mmHg may require treatment." - Schwartz's Principles of Surgery, 11e
"Severe hypertension (BP >220/120 mmHg) should be controlled because of increased risk of hemorrhagic transformation." - Barash Clinical Anesthesia, 9e
B. Before IV thrombolysis (alteplase/tPA) or thrombectomy (EVT)
BP must be reduced to and maintained at:
| Target | Value |
|---|---|
| Systolic | ≤185 mmHg |
| Diastolic | ≤110 mmHg |
- BP >185/110 is a contraindication to IV tPA.
- If this target cannot be achieved, the patient is no longer a tPA candidate.
First-line agents (per AHA/ASA, Tintinalli's EM):
| Drug | Dose |
|---|---|
| Labetalol | 10-20 mg IV over 1-2 min, may repeat x1 |
| Nicardipine infusion | Start 5 mg/h; titrate up by 2.5 mg/h q5-15 min; max 15 mg/h |
| Clevidipine infusion | Start 1-2 mg/h; double q2-5 min; max 21 mg/h |
C. During and after tPA/reperfusion therapy
Maintain BP <180/105 mmHg for at least 24 hours post-thrombolysis.
| BP Reading | Action |
|---|---|
| Systolic 180-230 or DBP 105-120 | Labetalol IV infusion 2-8 mg/min, or Nicardipine, or Clevidipine |
| DBP >140 mmHg | Consider sodium nitroprusside 0.5-10 mcg/kg/min (increases ICP - caution) |
Monitoring frequency after tPA:
- 0-2 h: every 15 min
- 3-8 h: every 30 min
- 9-24 h: every 60 min
D. KEY 2026 AHA/ASA UPDATE - Intensive lowering is NOT recommended
The 2026 AHA/ASA guideline (PMID 41582814, published January 2026) changed the previous approach:
Aggressive BP lowering after IV thrombolysis or EVT offers no functional benefit and may be harmful following EVT. Therefore, systolic BP reduction to <140 mmHg is NOT recommended, even after complete reperfusion.
This reverses prior thinking that earlier aggressive lowering might reduce hemorrhagic transformation risk post-reperfusion.
2. Intracerebral Hemorrhage (ICH)
| Initial SBP | Target | Evidence |
|---|---|---|
| 150-220 mmHg | Lower to 130-150 mmHg | AHA/ASA endorses; INTERACT2 showed improved outcomes trend |
| ≥220 mmHg | Aggressive reduction with continuous IV infusion + frequent monitoring | Guideline consensus |
- INTERACT2 trial: target SBP <140 mmHg vs. <180 mmHg - 52% vs. 55.6% death/major disability at 90 days (p=0.06, trend favoring lower target).
- ATACH2 trial: no outcome difference between groups; aggressive lowering increased renal adverse events.
- AHA/ASA current target for ICH: SBP 130-150 mmHg to avoid unintended hypoperfusion.
- If ICP monitoring in place: maintain cerebral perfusion pressure (MAP - ICP) = 60-70 mmHg.
"The most recent AHA/ASA guidelines for spontaneous ICH endorse achieving and maintaining a target SBP of 130-150 mmHg to avoid unintended hypoperfusion." - Harrison's 22e (2025)
ESO/EANS 2025 guideline (PMID 40401775) similarly endorses early BP lowering as "possibly beneficial" in ICH.
3. Secondary Prevention (Post-Stroke Long-Term)
- Target BP: <140/90 mmHg for most patients
- Target BP: <130/80 mmHg for those with 10-year ASCVD risk ≥10% (or diabetes, CKD)
- SPRINT trial data: SBP <120 mmHg reduces stroke/MI by 43% vs. SBP <140 mmHg
- Most guidelines support ACE inhibitor + thiazide diuretic combination as first-line
Quick Summary Table
| Situation | BP Target |
|---|---|
| AIS, no reperfusion therapy | Treat only if >220/120 mmHg |
| AIS, pre-tPA/EVT | Reduce to ≤185/110 mmHg |
| AIS, post-tPA/EVT (24 h) | Maintain <180/105 mmHg |
| AIS, post-EVT (2026 update) | Do NOT lower to <140 mmHg |
| ICH (SBP 150-220) | Target SBP 130-150 mmHg |
| ICH (SBP ≥220) | Aggressive IV reduction |
| Secondary prevention | <140/90 (most); <130/80 (high-risk) |
Sources: Tintinalli's Emergency Medicine; Harrison's Principles 22e (2025); Barash Clinical Anesthesia 9e; Schwartz's Surgery 11e; 2026 AHA/ASA AIS Guideline (PMID 41582814); ESO/EANS 2025 ICH Guideline (PMID 40401775)
This is a shared conversation. Sign in to Orris to start your own chat.